Universitätsklinikum Tübingen

Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanoma (2024) Brinker TJ, Chanda T, Hauser K, Hobelsberger S, Bucher TC, Garcia CN, Wies C, et al. Journal article [Not Available]. (2024) Berg T, Aehling NF, Bruns T, Welker MW, Weismüller T, Trebicka J, Tacke F, et al. Journal article Evaluation of the e-Mental Health Intervention Make It Training From Patients' Perspectives: Qualitative Analysis Within the Reduct Trial (2024) Krakowczyk JB, Truijens F, Teufel M, Lalgi T, Heinen JM, Schug C, Erim Y, et al. Journal article Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial. (2024) Meyer S, Bay J, Franz AR, Ehrhardt H, Klein L, Petzinger J, Binder C, et al. Journal article Psychosocial burden during corona: Results of a scoping review on families with children aged 0–5 years Psychosoziale Belastungen während Corona: Ergebnisse eines Scoping Reviews zu Familien mit Kindern zwischen 0 und 5 Jahren (2024) Ghezih S, Lux U, Löchner J, Chakraverty D, Neumann A, Renner I, Hager T, Ulrich SM Journal article A Primer on Sampling Rates of Ambulatory Assessments (2024) Seizer L, Schiepek G, Cornélissen-Guillaume G, Löchner J Journal article Affect and Emotion (2024) Löchner J, Schuller BW Authored book Transmembrane Serine Protease 2 and Proteolytic Activation of the Epithelial Sodium Channel in Mouse Kidney (2024) Sure F, Afonso S, Essigke D, Schmidt P, Kalo MZ, Nesterov V, Kißler A, et al. Journal article Neoadjuvant chemoradiotherapy in combination with deep regional hyperthermia followed by surgery for rectal cancer: a systematic review and meta-analysis (2024) Ademaj A, Stieb S, Gani C, Ott O, Marder D, Hälg RA, Rogers S, et al. Journal article A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 (2024) Hughes BG, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, et al. Journal article